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Abstract
Association of myeloproliferative neoplasm (MPN)
with lymphoproliferative neoplasm (LPN) has been
occasionally reported. The aim of this study, which
included 353 patients with polycythemia vera and
467 with essential thrombocythemia, was to assess
whether the risk of developing LPN is increased in
MPN patients. Expected numbers of LPN incident cases
were calculated based on 5-year age group, gender, and
calendar time–specific cancer incidence rates in the
general population of the same area. Standardized
incidence ratios were computed to estimate the relative
risk of developing LPN. Analyses were carried out for
the whole series and then separately for essential
thrombocythemia and polycythemia vera, gender, and
JAK2V617F genotype. With 4,421 person-years, we
found 11 patients developing LPN, including four
chronic lymphocytic leukemias, five non–Hodgkin’s
lymphomas, and two plasma cell disorders, after a
median interval time of 68 months from MPN diag-
nosis. Cumulative risk to develop LPN at 5 and
10 years was 0.93% (95% confidence interval, 0.39-2.22)
and 2.96% (95% confidence interval, 1.52-5.72), respec-
tively. There was a 3.44-fold increased risk of LPN
compared with the general population, ranging from
2.86 for plasma cell disorder to 12.42 for chronic
lymphocytic leukemia; the risk was significantly in-
creased in JAK2V617F mutated patients (5.46-fold)
and in males (4.52-fold). The JAK2V617F mutation
was found in lymphoid tumor cells in two of three
cases evaluated, indicating that, in some patients,
LPN originated in a JAK2V617F mutated common
lymphoid-myeloid hematopoietic progenitor cell. We
conclude that the risk of developing LPN is signifi-
cantly increased in MPN patients compared with the
general population. (Cancer Epidemiol Biomarkers
Prev 2009;18(7):2068–73)
Introduction
The Philadelphia chromosome–negative myeloprolifera-
tive neoplasms (MPN), according to the 2008 WHO
classification of tumors of hematopoietic and lymphoid
tissues, include the ‘‘classic’’ clinical entities polycythe-
mia vera (PV) and essential thrombocythemia (ET), in
addition to other entities (1). These are relatively indolent
neoplastic disorders, resulting in a modest reduction of
life span compared with the general population (2);
however, most patients ultimately suffer from one or
more severe, potentially fatal complications directly
attributable to the disease. These disorders have common
features that include their origin in a multipotent
hematopoietic stem cell; a relatively normal cellular
maturation; a striking overlap in clinical presentation;
the propensity to evolve into postpolycythemic or
postthrombocythemic myelofibrosis, or less frequently
each into the other; and the possibility to transform to
acute myeloid leukemia (3).
The molecular mechanisms at the basis of MPN have
remained largely unclear until the discovery in 2005 of a
single point mutation in the gene encoding the tyrosine
kinase Janus-activated kinase 2 (JAK2); the JAK2V617F
mutation, located in exon 14, is found in almost all
patients with PV and in f60% of those with ET or
primary myelofibrosis (4-7). The JAK2V617F mutation is
located in the JH2 pseudokinase domain of JAK2 and
results in the loss of autoinhibitory control and in
cytokine-induced hyperactivation of JAK2 (8). More
recently, mutations in MPL at codon 515 in ET or
primary myelofibrosis (9) and in exon 12 of JAK2 in PV
(10) have been reported. These mutations are considered
integral to the myeloproliferative process, but whether
they represent the original molecular lesion or a
secondary genetic event (11-14) and how one single
mutation can associate with different clinical phenotypes
(15) are still under investigation.
The MPNs are among the most frequent hematologic
neoplasms; according to a survey (16) based on the North
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American Association of Central Cancer Registries, they
summedup to an average 2001 to 2003 annual age-adjusted
incidence rate of 2.1 per 100,000. It is known that familial
clustering of these disorders also occurs, leading to the
suggestion of predisposition allele(s) (17-19). This hypoth-
esis is supported by results of a large Swedish study (20)
that pointed to a 5.7 relative risk of having PV, a 7.4 relative
risk of having ET, and a 7.5 relative risk of having
unclassified forms of MPN in the relatives of patients with
MPN. The coexistence of different clinical entities and of
JAK2V617F-positive and JAK2V617F-negative disorders in
the same family is noteworthy (18, 21, 22).
It is commonly held that the incidence of secondary
neoplasia or of another tumor of the hematopoietic
system is increased in MPN, but no large epidemiologic
study exists at this regard. In particular, the association
of MPN and a disorder of lymphoid system has been
sporadically reported in the literature. The aim of this
study was to evaluate the risk of developing lympho-
proliferative neoplasms (LPN) in a large cohort of
patients affected by ET and PV. We also had the
opportunity to genotype lymphoid cancer cells in three
JAK2V617F mutated patients, aiming at ascertaining
whether the two diseases originated from a common,
JAK2V617F mutated lymphoid-myeloid progenitor cell.
Results of this study indicate that patients with
MPN carry a statistically significant increased risk of
developing LPN compared with the general population
and that, although in some cases lymphoid cancer cells
harbor the V617F allele, the presence of mutation is not a
prerequisite for LPN to develop.
Patients and Methods
All consecutive patients with MPN newly diagnosed at
the Haematology Department of University of Florence
in the period 1980 to 2008 were identified and included
in the study. All patients were offered an active clinical
follow-up protocol. Information on individual demo-
graphics (sex, date of birth, age at diagnosis, area of
residence), baseline clinical characteristics, and
JAK2V617F mutational status was retrieved from
medical records and computerized, together with
information on newly diagnosed LPN during follow-up
and on vital status.
A total of 877 patients with MPN were retrieved from
the archive. According to residence,f85% of them were
residing in the provinces of Florence and Prato, an area
covered since 1984 by the Tuscany Cancer Registry. The
remainders were mostly residing in neighboring areas.
The diagnosis was reevaluated in all instances using
the original clinical records and bone marrow biopsy
when available; overall, there were 532 patients (61%)
who had a diagnosis fulfilling the WHO criteria (1) and
345 (39%) in whom the diagnosis fulfilled the Polycythe-
mia Vera Study Group criteria (23). Clinical history was
reviewed with special attention to the diagnosis of LPN
based on chart records. Diagnosis of LPN was made
according to the WHO criteria (1), and in all cases, the
original diagnosis was critically reviewed using chart
records, laboratory records (routine tests, immunophe-
notyping, conventional or molecular cytogenetics when
available), bone marrow biopsy, or lymph node biopsy.
This retrospective analysis was approved by the local
ethical committee of Azienda Ospedaliera-Universitaria
Careggi, according to the principles of the Helsinki
Declaration.
JAK2V617F Genotyping. Genotyping was done in
peripheral blood granulocytes collected by density gradi-
ent centrifugation to >95% purity. B and T lymphocytes
were purified from peripheral blood at the diagnosis of
Table 1. Characteristics of theMPN patients considered
in the study
PV ET
n 353 467
Males/females 237/116 154/313
Age (y), median (range) 61 (16-89) 57 (14-97)
Individual follow-up
duration (y), median (range)
3.4 (0.1-26.2) 3.2 (0.1-23.9)
Total follow-up (PY) 1,882 2,539
Leukocycte count (109/L) 9.63 (3.8-13.2) 9.0 (4.1-26.0)
Hemoglobin (g/L) 176 (148-24)* 140 (71-174)
Platelet count (109/L) 414 (125-1, 250) 800 (529-3, 125)
JAK2V617F positive, n (%)
c
169/172 (98.2) 215/336 (64.0)
Abbreviation: PY, person-years.
*Some patients had been already phlebotomized before a diagnosis of PV
could be firmly established.
cData refer to 508* patients genotyped (61.9% of total).
Table 2. Clinical and individual characteristics of the 11 patients with MPN who developed LPN during the
follow-up
Case no. Gender MPN Age at diagnosis
of MPN (y)
Cytoreductive
treatment
LPN Interval between MPN
and LPD diagnosis (mo)
JAK2V617F
01 M PV 66 Yes MM IgAE 79 +
02 M PV 59 Yes CLL 77 NA
03 M PV 74 Yes CLL 23 NA
04 F PV 64 Yes DLBC-NHL 68 +
05 M PV 64 No MC-NHL 20 +
06 M PV 43 No WD 112 NA
07 M PV 69 No NHL 131 NA
08 F ET 65 Yes CLL 71 +
09 M ET 64 No CLL 25 +
10 M ET 65 Yes T-NHL 28 +
11 F ET 70 No MC-NHL 7 NA
Abbreviations: MM, multiple myeloma; CLL, chronic lymphocytic leukemia; DLBC, diffuse large B cell; NHL, non–Hodgkin’s lymphoma; MC, mantle
cell; WD, Waldenstrom disease; T-NHL, T-cell NHL; NA, not available.
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MPN using immunomagnetic beads, as reported previ-
ously (24). In a patient with chronic lymphocytic leukemia,
neoplastic cells (CD19+CD5+CD20+) were sorted from
peripheral blood mononuclear cells with a FACSAria
flow cytometer (Becton Dickinson) using fluorochrome-
conjugated anti-CD19, anti-CD5, and anti-CD20 monoclo-
nal antibodies. DNA was obtained from granulocytes or
sorted lymphoid cells using the QIAmp DNA blood kit
(Qiagen GmbH) and quantified with the NanoDrop
technology. QIAmp DNA micro kit (Qiagen) was used
to isolate genomic DNA from paraffin-embedded biopsies
of lymph nodes or other tissues. Genotyping for
JAK2V617F mutation (5) was done with a quantitative
real-time PCR assay (25).
Statistical Analysis. For each subject, the period at
risk was defined from the date of diagnosis of MPN to
the date of incidence of LPN, date of death, or date of the
more recent clinical examination, whichever came first,
and person-years were calculated. The expected number
of incident cases of LPN in our series was calculated on
the basis of 5-y age group, gender, and calendar time–
specific cancer incidence rates in the general population
of the same area applied to the person-years at risk in
each 5-y age group, gender, and period-specific category
of patients during the follow-up period. The specific
cancer incidence rates were provided by the Tuscany
Cancer Registry, which is active in the provinces of
Florence and Prato since 1984 and provides routinely
cancer incidence data for the area (f1,161,000 inhab-
itants). The degree to which incidence of LPN in this
series of patients differed from the general population
was measured by the ratio of observed to expected cases.
This ratio, known as standardized incidence ratio (SIR), is
a reliable estimate of the relative risk of developing LPN
in the series of MPN patients in comparison with the
general population of the area. Briefly, when a SIR results
significantly higher than unit, then LPN risk among
patients is significantly increased in comparison with the
general population of the area. SIRs were estimated for
LPN both as a whole and for specific histologic types,
together with 95% confidence intervals (95% CI), calcu-
lated under the assumption of a Poisson distribution for
cancer cases observed in the follow-up period. Analyses
were first carried out for the whole series and then
separately for ET and PV, gender, JAK2V617F mutational
status, and by latency from diagnosis of MPN (0-5 and
>5 y). SIR estimates are presented only for specific
histologic types with at least two cases diagnosed.
Cumulative risks at 5 and 10 y were also calculated.
Results
Patient Characteristics. Of the 877 subjects initially
identified, 57 were excluded from the study because they
had been lost to follow-up after the first visit. The clinical
and laboratory features at diagnosis of the remaining 820
patients (353 PV and 467 ET) who remained in active
follow-up are summarized in Table 1. There were 391
males (48%); median age at diagnosis of MPN was 59
years, and the median follow-up period was 3.3 years.
During the follow-up, 20 patients (16 with ET and 4 with
PV) died; there were 11 disease-related deaths (transfor-
mation to acute leukemia), one patient died of lung
cancer whereas other causes were infections or multi-
organ failure. A total of 4,421 person-years were available
for analysis (2,450 person-years for females and 1,971
person-years for males); ET and PV provided 2,539 and
1,882 person-years, respectively.
JAK2V617F mutational status was available in 508
patients (61.9%), of whom 384 (75.6%) were mutated,
98.2% (169 of 172) and 64.0% (215 of 336) among PV and
ET patients, respectively. Overall, 1,643 person-years were
contributed by patients harboring the V617Fmutation and
644 person-years by those who were JAK2 unmutated.
Table 3. Distribution of LPN in the series of MPN
patients, overall and by specific subtype; number of
observed and expected cases and relative risks as
estimated by SIRs and 95% CIs
No.
observed*
No.
expected
c
SIR
(95% CI)
All MPN patients
LPN (all types) 11 3.20 3.44 (1.90-6.20)
NHL 5 1.45 3.44 (1.43-8.27)
CLL 4 0.32 12.42 (4.66-33.09)
PCD 2 0.70 2.86 (0.72-11.43)
PV
LPN (all types) 7 1.57 4.45 (2.12-9.34)
NHL 3 0.71 4.25 (1.37-13.17)
CLL 2 0.16 12.35 (3.09-49.38)
PCD 2 0.35 5.77 (1.44-23.08)
ET
LPN (all types) 4 1.63 2.45 (0.92-6.54)
NHL 2 0.75 2.68 (0.67-10.71)
CLL 2 0.16 12.49 (3.12-49.94)
JAK2V617F positive
LPN (all types) 6 1.10 5.46 (2.45-12.15)
NHL 3 0.53 5.71 (1.84-17.72)
CLL 2 0.10 19.14 (4.79-76.52)
Latency
V5 yb 5 1.72 2.90 (1.21-6.97)
>5 y
b
6 1.48 4.06 (1.82-9.03)
Abbreviation: PCD, plasma cell disorder.
* LPN cases newly diagnosed in MPD patients (only LPN subtypes with
at least two observed cases are included in the table).
cExpected cases of LPN according to incidence rates in the general
population of the area applied to the number of person-years in the study
follow-up.
bAfter the original MPD diagnosis.
Table 4. Distribution of LPN in the series of MPN
patients, overall and by specific subtype according to
gender; number of observed and expected cases and
relative risks as estimated by SIRs and 95% CIs
Gender No.
observed*
No.
expected
c
SIR
(95% CI)
Male
LPN (all types) 8 1.77 4.52 (2.26-9.03)
NHL 3 0.78 3.85 (1.24-11.95)
CLL 3 0.19 15.67 (5.05-48.58)
PCD 2 0.38 5.23 (1.31-20.90)
Female
LPN (all types) 3 1.43 2.10 (0.68-6.50)
NHL 2 0.67 2.97 (0.74-11.86)
*LPN cases newly diagnosed in MPD patients (only LPN subtypes with at
least two observed cases are included in the table).
cExpected cases of LPN according to incidence rates in the general
population of the area applied to the number of person-years in the study
follow-up.
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Epidemiology of LPN in the Series of MPN Patients.
The development of LPNwas recorded during the follow-
up in 37 patients (4.5%); of these, 14 had a diagnosis of ET
and 23 of PV. Twenty-six patients, 10 with ET and 16 with
PV, were diagnosed with a monoclonal gammopathy of
undetermined significance; due to the high occurrence of
this abnormality in the general population, its unclear
neoplastic significance, and the lack of specific incidence
rate in the general population, no estimate of SIRwas done
and patients were still considered in follow-up. Of the 11
LPN considered, there were four chronic lymphocytic
leukemia, five non–Hodgkin’s lymphomas, and two
plasma cell disorders, represented by one multiple
myeloma and one Waldenstrom disease. Seven cases
occurred in patients with PV (7 of 11, 63.6%) and four in
patientswith ET (4 of 11, 36.4%; Table 2). Themedian age at
diagnosis of LPN was 70 years, and the median follow-up
after the diagnosis of LPN was 5.7 years. The median
interval time from diagnosis of MPN to LPN was 68
months (range, 7-131). Six of the 11 patients (54.5%) were
on cytoreductive treatment (hydroxyurea) from a mean
time of 51months (range, 12-84)whenLPNwasdiagnosed.
Table 3 shows the observed and the expected number
of LPN cases diagnosed in the whole series and the
relative risks in comparison with the general population
of the area estimated by SIRs. Overall, the incidence of
LPN showed a significant 3.44-fold (95% CI, 1.90-6.20)
increase in the entire series; the risk was significantly
increased in PV (SIR, 4.45; 95% CI, 2.12-9.34) and, falling
short of statistical significance, in ET (SIR, 2.45; 95% CI,
0.92-6.54). Among the different histologic subtypes, the
risk of developing LLC was >12-fold increased in both
PV and ET, based on two observed cases in each disease
(Table 3). Considering non–Hodgkin’s lymphoma, the
risk was 4.25 (95% CI, 1.37-13.17) in PV and 2.68 (95% CI,
0.67-10.71) in ET, based on three and two cases,
respectively. Finally, there was a significantly increased
risk in patients harboring the JAK2V617F mutation (n = 6
cases; SIR, 5.46; 95% CI, 2.45-12.15) whereas no cases
emerged among JAK2 wild-type subjects. Overall, the
risk to develop LPD increased with increasing latency
from the original MPN diagnosis (SIR, 2.90 in the first 5
years of follow-up; SIR, 4.06 in the period after 5 years
from diagnosis).
In Table 4, the distribution of LPN in relation to gender
is shown. The risk of developing LPN was 4.52-fold (95%
CI, 2.26-9.03) higher than expected in male patients,
whereas among females, a nonsignificant increase of
2.10-fold (95% CI, 0.68-6.50) emerged.
Cumulative risks to develop LPN at 5 and 10 years
after the original diagnosis of MPN were estimated as
0.93% (95% CI, 0.39-2.22) and 2.96% (95% CI, 1.52-5.72),
respectively (Fig. 1).
JAK2V617F Genotype in Lymphoid Cancer Cells. In
three JAK2V617F mutated patients, one with PV and two
with ET who developed LPN during the course of their
MPN, we were able to genotype cancer lymphoid cells.
There were one case of mediastinal diffuse large B-cell
non–Hodgkin’s lymphoma, one chronic lymphocytic
leukemia, and one enteropathy-type T-cell ileal lympho-
ma (CD3+/CD56+/BCL2+/Mib1+ >90% of the cells;
Table 5). In case of lymphomas, we extracted DNA from
paraffin-embedded tumor biopsies, whereas in case of
chronic lymphocytic leukemia, we sorted neoplastic B
cells according to their CD19/CD5/CD20 phenotype to a
purity of >97%. We found that, in the diffuse large B-cell
non–Hodgkin’s lymphoma and the chronic lymphocytic
leukemia case, the lymphoid tumor cells harbored the
V617F allele, whereas T cells from the ileal lymphoma
were wild type (Table 5). In the two patients who
developed a non–Hodgkin’s lymphoma, we could also
genotype B and T cells that had been purified from the
peripheral blood at the time of MPN diagnosis; we found
a concordance of the mutational status of tumor
lymphoid cells and peripheral blood–derived T and B
lymphocytes (Table 5).
Discussion
The association of a Philadelphia chromosome–negative
MPN and LPN in the same patient is a relatively
Table 5. JAK2V617F mutational status of peripheral blood cells and neoplastic lymphoid cells in three cases of LPN
that occurred during the follow-up of MPN patients
Case no. LPN MPN JAK2V617F mutational status
GN* CD3*,
c
CD19*,
c
Tumor cells
c
04 DLBC-NHL PV V617F V617F V617F V617F
08 CLL ET V617F n.a. n.a. V617F
10 T-NHL ET V617F WT WT WT
Abbreviations: WT, wild type.
*Genotyping was done on cells collected at diagnosis.
cDNA of tumor cells was extracted from tumor biopsies in case of NHL or from sorted clonal B cells in case of CLL.
n.a., not available
Figure 1. Kaplan-Meier’s cumulative risk of developing LPN
after MPN diagnosis.
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uncommon event, originally described in 1953 (26). After
a revision of the literature (updated to December 2008),
we identified at least 60 publications reporting single-
case association of ET or PV with different types of LPN;
these included chronic lymphocytic leukemia, which
was the most represented, Hodgkin’s disease, non–
Hodgkin’s lymphoma, and multiple myeloma.
To our knowledge, this is the largest series reported
that included >800 patients with the two commonest
MPNs (i.e., PV and ET). The single-center design of this
analysis represents, in our opinion, an added value for
the interpretation of data, in particular with regard to the
epidemiologic design of the study. In fact, most patients
were residing in a well-defined area in Tuscany where a
Cancer Registry is collecting information since 25 years,
allowing us to have a large and representative series of
LPN incident cases to estimate stable incidence rates in
the general population and, therefore, a reliable number
of expected cases in this study series. Furthermore, the
availability of incidence rates in the same population
guaranteed that the role of environmental variables
potentially influencing the risk of developing LPN was
kept under control.
The results of this study indicate that the risk of
developing LPN is significantly increased in patients
with MPN compared with the general population, in
particular in those with PV and in males. The overall
frequency of LPN in this series was 1.34% of all MPN,
comparable with the 1.6% reported in a recent series of
499 ET patients that enumerated eight cases of LPN (27).
The cumulative risks of developing LPN at 5 and 10
years were between 1% and 3%. Furthermore, the risk
was significantly higher in patients harboring the
JAK2V617F mutation than in wild type. In addition, it
is worthy to note that the risk was as high as 12-fold in
case of chronic lymphocytic leukemia. Our results also
suggest that the risk tends to increase with increasing
duration of the MPN, with a SIR of >4 after 5 years of
follow-up. Therefore, it is also likely that the true
incidence of LPN is underestimated in this analysis if
we take into account that the median time for LPN to
develop after the diagnosis of MPN (72 months) was
almost twice the median follow-up time (39 months) of
the whole series.
The design of the study did not allow drawing of any
conclusion about a possible causative or contributing
role of cytotoxic therapy instituted for the control
of MPN; however, it is of note that in most single
cases reported in the literature, the two diseases
were diagnosed simultaneously, in the absence of any
treatment.
A large population-based case-control study in
Sweden described a 5-fold to 7-fold elevated risk of
developing MPN among first-degree relatives of MPN
patients, supporting susceptibility genes predisposing to
these disorders in the population (20). In addition,
defined single-nucleotide polymorphisms in JAK2 were
found to associate with PV or ET, rather than primary
myelofibrosis, and one single-nucleotide polymorphism
in EPOR to significantly associate with PV only among
the MPN (28). Data from current study would imply that
similar predisposition allele(s) underlie the risk of
developing LPN in patients affected by MPN. It is also
of relevance that activation of JAK2 by the V617F
mutation has been shown to favor a condition of genetic
instability in cells forced to express the mutated gene, as
well as in ex vivo isolated CD34+ hematopoietic progen-
itor cells from PV or primary myelofibrosis patients;
these cells showed an increased homologous recombina-
tion rate, spontaneous RAD51 foci formation, and high
mutagenesis at different loci (29). Therefore, the finding
in our series that increased risk of LPN was particularly
associated with a JAK2V617F mutated status is intrigu-
ing. On the other hand, the fact that, in one of three cases
examined, the lymphoid cancer cells were JAK2 wild
type suggested that the presence of JAK2V617F is not
essential for LPN to develop in the course of MPN. There
are at least two possible explanations: one is that the
MPN and LPN originated from different progenitors and
the other is that both disorders originated from a
common lymphoid-myeloid progenitor cell, hinted by a
first genetic insult followed first by the JAK2V617F
mutation leading to the MPN phenotype and later by
(an)other mutation(s) favoring the development of LPN.
In conclusion, we found a significantly increased
risk of developing LPN in a large population of patients
with PV or ET that ranged from 3-fold for any LPN
up to 12-fold in case of chronic lymphocytic leukemia.
Indirectly, these results are in support of the theory of a
global genetic instability of pluripotent hematopoietic
progenitors in the MPN as well as of generic suscepti-
bility alleles. This information could also be of relevance
for interpreting results of ongoing gene mapping and
candidate gene studies in patients with MPN, which
recently resulted in highlighting novel, still largely to be
defined interactions between germ line haplotypes and
acquired mutations at the JAK2 locus (30).
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